Objective: To characterize pathogenic effects of antibodies to dipeptidyl-peptidase-like protein 6 (DPPX), a subunit of Kv4.2 potassium channels, on gut and brain neurons.
In 2013, a novel autoimmune encephalitis associated with antibodies to dipeptidyl-peptidaselike protein 6 (DPPX), an auxiliary subunit of Kv4.2 potassium channels, was identified in 4 patients whose clinical presentation included agitation, hallucinations, confusion, myoclonus, tremor, and seizures. 1 An additional 3 patients with anti-DPPX antibodies and a distinct syndrome resembling progressive encephalomyelitis with rigidity and myoclonus (PERM) were subsequently described. 2 Recently, clinical features and outcomes were characterized in 20 patients with anti-DPPX encephalitis. 3 Remarkably, 14 of the 27 patients with anti-DPPX encephalitis reported so far had pronounced gastrointestinal symptoms, including severe diarrhea in 10 and constipation in 4 patients. [1] [2] [3] DPPX is a membrane glycoprotein involved in increasing the surface expression and channel conductance of Kv4.2 channels. [4] [5] [6] Although its function and the expression of DPPX in hippocampus, cerebellum, striatum, and myenteric plexus 1, 7 are compatible with the clinical symptoms of anti-DPPX encephalitis, the pathogenic mechanisms of anti-DPPX antibodies have not been characterized. We report on a new patient with anti-DPPX encephalitis and analyze potential pathogenic effects of anti-DPPX-antibody-containing sera on gut and brain neurons.
METHODS Standard protocol approvals, registrations, and patient consents. The study was approved by the ethical committees of the involved institutions. Written informed consent was obtained from all patients participating in this study.
Details of the additional patients with anti-DPPX encephalitis analyzed in this study and the methods employed in this work are provided in appendix e-1 on the Neurology ® Web site at Neurology.org.
Case report. In April 2012, a 68-year-old man developed severe diarrhea, which lasted for about 2 months, was associated with 20-kg weight loss, and remained unexplained on gastrointestinal workup including gastroscopy, colonoscopy, and microbiologic stool examinations ( figure 1A ). The patient subsequently noted progressive topographical disorientation (e.g., he could not find the way to his local supermarket) and short-term memory problems, starting in September 2012. He also developed tremor of the left more than the right hand, gait unsteadiness, and complained of an increased need for sleep, with up to 4 hours of daytime sleep in addition to regular sleep at night. On admission to the hospital, in October 2013, he had a mild cerebellar syndrome, mild rigidity of the arms, and a resting and postural tremor in his hands. In a detailed neuropsychological examination he was oriented, but had a reduced attention span and impairment of anterograde memory for verbal contents, consistent with amnestic mild cognitive impairment.
Cranial MRI was normal except for moderate microangiopathic leukoencephalopathy. CSF examination revealed a normal cell count and protein (data on oligoclonal bands/immunoglobulin G [IgG] synthesis not available). Whole-body fluorodeoxyglucose positron emission CT showed no neoplasia, but demonstrated a markedly reduced uptake in the caudate nuclei bilaterally and a moderately reduced uptake in the frontal cortex (figure 1B). Broad screening for antineuronal as well as gliadin (IgG and immunoglobulin A) serum autoantibodies was negative. However, high titer (1:1,000) IgG serum antibodies to DPPX were independently detected in 2 laboratories (Euroimmun, Lübeck, Germany; Dalmau Laboratory, Barcelona, Spain), using HEK293 cells overexpressing DPPX ( figure 1C ). The patient's serum staining pattern in cultured murine hippocampal neurons overlapped with that of a commercial monoclonal antibody against DPPX ( figure 1D ).
The patient was treated with IV methylprednisolone (3 3 1 g/day) followed by tapered oral corticosteroids and IV immunoglobulins. This was associated with a decline of the anti-DPPX antibody titer and marked improvement of the patient's cognitive as well as motor symptoms with almost complete return to his premorbid level of functioning ( figure 1A) .
RESULTS Anti-DPPX-antibody-containing sera cause hyperexcitability of enteric nervous system neurons.
Given the prominent gastrointestinal symptoms in patients with anti-DPPX encephalitis, we analyzed the effects of our patient's (patient 1) serum on enteric neurons. Indirect immunofluorescence on mouse and monkey gut tissue sections and on guinea pig ileum whole-mount preparations confirmed binding of the patient's serum and purified IgG, but not of a healthy control serum, to enteric neurons in the myenteric and submucous plexus (figure 2, A-C). Consistent with this binding, brief application (200-400 ms) of patient 1 serum to guinea pig myenteric or human submucous plexus preparations resulted in increased activity of enteric neurons. The same result was obtained with serum of a previous patient (patient 2) with anti-DPPX encephalitis. In contrast, application of sera from healthy controls (see figure e-1 for additional traces of healthy control sera) was not associated with increased enteric neuron activity (figure 2, D and E). Both the percentage of guinea pig myenteric plexus neurons that fired action potentials as well as the frequencies of these action potentials were significantly higher after stimulation with the 2 anti-DPPX-antibody-containing sera than after stimulation with healthy control serum. Similar, but even more pronounced, effects were observed in experiments using human submucous plexus preparations (figure 2, F and G). Likewise, application of purified IgG from patient 1, but not from a healthy control, to human submucous plexus preparations caused increased enteric neuron activity (figure e-2).
Binding of anti-DPPX serum to excitatory and inhibitory synapses of CNS neurons and association with Kv4.2.
Indirect immunofluorescence with serum from patient 1 on rat cerebellum demonstrated marked staining of the cerebellar glomeruli within the granule cell layer together with a faint staining of the molecular layer, but not of Purkinje cells and white matter (figure 3A). In mouse hippocampus sections, the patient's serum strongly and homogeneously stained the neuropilar regions of the cornu ammonis (most prominent for the mossy fiber terminals in the stratum lucidum) and dentate gyrus ( figure 3B ). Incubation of living murine hippocampal neurons with serum and purified IgG from patient 1 revealed a punctuate staining pattern at the neuronal surface ( figure 3C ). Double staining with the microtubular protein Map2 indicated a somatodendritic localization of the signal (figure 3D). Further characterization using synapsin as a pansynaptic marker demonstrated a close, but not complete, colocalization of the patient's serum signal with synaptic structures (figure 4A). Sera of 3 further patients (2-4) with anti-DPPX encephalitis revealed a similar somatodendritic, perisynaptic staining pattern (figure e-3). Double immunofluorescence with serum from patient 1 and antibodies to VGLUT 1 and 2 (markers of excitatory connections) or to VGAT (a marker of inhibitory synapses) indicated that both types of synaptic connections were labeled (figure 4, B and C). Double staining with serum from patient 1 and antibodies to Kv4.2 showed a close association of the antigenic targets ( figure 4D) . figure 5, A and B) . Likewise, incubation of hippocampal neurons with serum from patient 1, but not with control serum, caused a decreased neuronal membrane expression of DPPX ( figure 5, C and D) . DISCUSSION The clinical findings of our newly identified patient with anti-DPPX encephalitis are reminiscent of those reported in the original series 1 rather than the PERM-like presentation described in 3 patients with anti-DPPX antibodies. 2 A noteworthy feature was transient hypersomnia, consistent with the recent observation of sleep disturbances in 9 of 20 patients with anti-DPPX encephalitis. 3 With increasing recognition of new patients, the clinical spectrum of anti-DPPX encephalitis is likely to expand further, similar to other autoimmune encephalitides. [8] [9] [10] [11] This report confirms that anti-DPPX encephalitis may respond to immunotherapy. Thus, in clinical practice, the combination of prodromal diarrhea with subsequent even mild neurologic and psychiatric symptoms should elicit testing for anti-DPPX antibodies. We observed a significantly increased activity of enteric neurons after application of anti-DPPX sera to guinea pig and human myenteric plexus preparations. The rapid onset of this effect is remarkable and likely to be due to an immediate modulation of the electrophysiologic properties of gastrointestinal DPPX/Kv4.2 complexes upon binding of anti-DPPX antibodies to their antigenic target, rather than to internalization of DPPX or Kv4.2. Our findings are consistent with the enhanced neuronal excitability observed in DPPX knockouts 12 and indicate that genetic ablation or antibody-mediated alteration of DPPX may result in neuronal hyperexcitability. It thus seems conceivable that the initial severe diarrhea of patients with anti-DPPX encephalitis is related to anti-DPPX-antibody-induced hyperexcitability of enteric neurons, leading to gastrointestinal hyperactivity. Nevertheless, the occasional occurrence of gastrointestinal hypomotility 2,3 suggests that in certain instances anti-DPPX antibodies could also lead to loss Binding of anti-dipeptidyl-peptidase-like protein 6 serum to excitatory and inhibitory synapses and association with Kv4.2 or exhaustion of enteric neurons, perhaps in more chronic stages of the disease. The staining pattern of our patient's serum in cerebellum and hippocampus corresponded to the known distribution of DPPX in the CNS. [1] [2] [3] [4] 7 Extending previous observations, immunocytochemical characterization of the binding pattern in murine hippocampal neurons demonstrated a somatodendritic, perisynaptic localization in both glutamatergic and GABAergic synapses and a close colocalization with Kv4.2, consistent with DPPX being an auxiliary subunit of Kv4.2.
Receptor internalization in cultured neurons has been identified as a pathogenic mechanism in several encephalitides mediated by antibodies to neuronal surface proteins and is a likely correlate of the reversibility of clinical symptoms if those proteins can be re-expressed at the cellular surface. [13] [14] [15] [16] Likewise, our patient's purified IgG and serum reduced the expression of DPPX in membranes of hippocampal neurons. Of note, this was accompanied by a similar reduction of Kv4.2. As under physiologic conditions DPPX enhances cell surface expression of Kv4.2, 4 it seems plausible that anti-DPPX antibodies interfere with the DPPXmediated membrane targeting of Kv4.2. Similar to the hyperexcitability of CNS neurons observed in DPPX knockouts, 12 downregulation of DPPX and Kv4.2 by Antibody-mediated downregulation of dipeptidyl-peptidase-like protein 6 and Kv4.2 from neuronal membranes (A) Membrane fractions were generated from cultured hippocampal neurons and processed for immunoblotting after preincubation of neurons with patient 1 or control immunoglobulin G (IgG) for 3 days (1:100, daily application). Immunoblots were developed with commercial anti-dipeptidyl-peptidase-like protein 6 (DPPX), Kv4.2, and Na 1 /K 1 -ATPase antibodies. Glycerinaldehyde-3-phosphate dehydrogenase (GAPDH) was used as loading control. (B) Quantification of DPPX, Kv4.2, and Na 1 /K 1 -ATPase expression in relation to the GAPDH signal and normalized to untreated cultures. Data are means 6 SEM from 3 (DPPX, Kv4.2) or 2 (Na 1 /K 1 -ATPase) independent experiments. (C) Membrane fractions were generated from cultured hippocampal neurons and processed for immunoblotting after preincubation of neurons with patient 1 or control serum for 3 days (1:100, daily application). Fractions were tested for DPPX expression using a commercial antibody. Actin was used as loading control. (D) Quantification of DPPX expression in relation to the actin signal, normalized to untreated cultures. Data are means 6 SEM from 3 independent experiments. Statistical significance was assessed by Mann-Whitney U test.
anti-DPPX serum is expected to result in CNS hyperexcitability, which may underlie the neurologic manifestations of anti-DPPX encephalitis. This work identifies potential pathogenic mechanisms of anti-DPPX antibodies in anti-DPPX encephalitis, supporting a pathogenic role of anti-DPPX antibodies in this novel form of autoimmune encephalitis. 
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